TGTX TG THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1001316 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY68.8%
TTM net income YoY-76.3%
TTM EPS YoY-75.8%
Revenue 3-yr CAGR67.9%
Net income 3-yr CAGR—
Margins
Gross margin82.7%
Operating margin21.5%
Net margin11.8%
FCF margin9.5%
EBITDA margin21.5%
Returns
ROE18.0%
ROA8.1%
ROIC (approx.)16.4%
Asset turnover0.69x
Leverage & solvency
Liabilities / assets64.1%
Debt / equity1.30x
Current ratio4.50x
Interest coverage4.14x
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio1.5%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $259.94M | $240.34M | $204.92M | $192.57M | $161.71M | $141.15M | $120.86M | $108.19M |
| Cost of revenue | $42.08M | $41.19M | $33.51M | $38.14M | $28.09M | $18.94M | $15.54M | $15.40M |
| Gross profit | $217.86M | $199.14M | $171.41M | $154.43M | $133.62M | $122.21M | $105.31M | $92.79M |
| R&D expense | $51.29M | $95.34M | $48.40M | $41.19M | $40.88M | $31.78M | $46.36M | $23.87M |
| SG&A expense | $80.67M | $82.13M | $88.22M | $62.74M | $63.37M | $55.59M | $50.33M | $38.96M |
| Operating income | $85.90M | $21.67M | $34.80M | $50.49M | $29.36M | $34.84M | $8.62M | $29.95M |
| Interest expense | $15.82M | $16.57M | $7.67M | $6.53M | $6.72M | $6.72M | $6.76M | $7.06M |
| Pretax income | $73.86M | $10.23M | $20.36M | $45.09M | $25.91M | $30.92M | $5.47M | $25.45M |
| Income tax | $18.40M | $2.45M | $586,000 | $22.06M | -$364.99M | $2.73M | $408,000 | $2.12M |
| Net income | $55.46M | $7.78M | $19.78M | $23.04M | $390.89M | $28.19M | $5.06M | $23.33M |
| EBITDA | $85.97M | $21.73M | $34.83M | $50.52M | $29.38M | $34.86M | $8.63M | $29.96M |
| EPS (basic) | 0.39 | 0.05 | 0.14 | — | 2.69 | 0.19 | 0.03 | — |
| EPS (diluted) | 0.35 | 0.05 | 0.12 | — | 2.43 | 0.17 | 0.03 | — |
| Weighted avg. shares (diluted) | 155.93M | 157.28M | 160.06M | — | 161.00M | 162.56M | 162.77M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $429.38M | $482.57M | $442.21M | $79.15M | $74.08M | $129.13M | $132.14M | $179.89M |
| Short-term investments | $75.30M | $69.67M | $72.22M | $62.82M | $57.50M | $122.74M | $144.10M | $131.11M |
| Receivables | $416.82M | $401.56M | $392.05M | $305.63M | $265.38M | $231.52M | $190.12M | $129.19M |
| Inventory | $194.32M | $147.97M | $129.03M | $125.59M | $146.95M | $155.20M | $157.76M | $110.46M |
| Current assets | $1.17B | $1.15B | $1.09B | $630.76M | $599.76M | $663.96M | $644.51M | $566.36M |
| Total assets | $1.59B | $1.64B | $1.53B | $1.06B | $1.03B | $702.61M | $656.69M | $577.69M |
| Current liabilities | $260.53M | $268.49M | $187.11M | $153.76M | $156.81M | $171.89M | $160.21M | $90.68M |
| Long-term debt | $745.63M | $745.39M | $745.14M | $245.65M | $245.34M | $245.04M | $244.73M | $244.43M |
| Total debt | $745.63M | $745.39M | $745.14M | $245.65M | $245.34M | $245.04M | $244.73M | $244.43M |
| Total liabilities | $1.02B | $1.04B | $945.71M | $415.23M | $417.81M | $426.18M | $419.40M | $355.33M |
| Shareholders' equity | $572.13M | $604.08M | $583.13M | $648.02M | $607.22M | $276.43M | $237.29M | $222.36M |
| Net debt | $316.26M | $262.81M | $302.93M | $166.50M | $171.26M | $115.91M | $112.59M | $64.53M |
| Shares outstanding | 151.16M | 153.08M | 153.09M | 155.31M | 155.21M | 158.03M | 158.17M | 155.84M |
| Cash flow statement | ||||||||
| Operating cash flow | $45.23M | $39.26M | -$17.89M | $19.66M | -$23.15M | $7.44M | -$28.71M | -$25.64M |
| Capital expenditure | $282,000 | $293,000 | $51,000 | $67,000 | $80,000 | $42,000 | $25,000 | $21,000 |
| Free cash flow | $44.95M | $38.97M | -$17.95M | $19.59M | -$23.23M | $7.39M | -$28.74M | -$25.66M |
| Investing cash flow | $1.33M | $1.03M | -$9.86M | -$15.64M | $46.36M | -$3.99M | -$12.93M | $15.79M |
| Financing cash flow | -$99.75M | $85,000 | $390.83M | $1.06M | -$78.24M | -$6.44M | -$6.10M | -$6.07M |
| Depreciation & amortization | $73,000 | $53,000 | $32,000 | $21,000 | $17,000 | $13,000 | $8,000 | $9,000 |
| Stock-based compensation | $24.70M | $27.88M | $19.95M | $15.65M | $17.69M | $16.40M | $14.97M | $11.95M |
Free plan shows the latest 8 periods; Pro shows all 64 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.